Details:
The collaboration aims to support Protheria for the development and manufacturing KRP203 (mocravimod), which is being evaluated in the late-stage for the treatment of adult acute myeloid leukemia.
Lead Product(s): Mocravimod
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Priothera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 18, 2024
Details:
EUROAPI will focus on lipids that are currently being tested as part of Phase I/II clinical trials that will support Sanofi’s mRNA vaccines platform, targeting indications including Flu.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 30, 2022